Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have earned a consensus recommendation of “Moderate Buy” from the twenty-four brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eighteen have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $298.09.

A number of brokerages have commented on ALNY. Canaccord Genuity Group lifted their price objective on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Scotiabank boosted their price objective on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. StockNews.com raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, December 27th. Piper Sandler reissued an “overweight” rating and set a $296.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Finally, Barclays raised their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st.

Alnylam Pharmaceuticals Trading Up 0.3 %

Shares of ALNY stock opened at $234.28 on Friday. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The stock has a market capitalization of $30.22 billion, a price-to-earnings ratio of -89.42 and a beta of 0.34. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The stock’s 50-day moving average price is $252.99 and its 200-day moving average price is $257.91.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. Alnylam Pharmaceuticals’s revenue was down 33.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.15 earnings per share. Equities research analysts predict that Alnylam Pharmaceuticals will post -2.21 EPS for the current fiscal year.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the transaction, the executive vice president now owns 13,191 shares in the company, valued at $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 5,219 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the sale, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,122 shares of company stock worth $2,540,455. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Large investors have recently made changes to their positions in the business. Ashton Thomas Private Wealth LLC purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $26,000. Huntington National Bank grew its stake in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at about $29,000. Washington Trust Advisors Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $42,000. Finally, True Wealth Design LLC boosted its stake in Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 153 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.